CVS Health (CVS) to Release Earnings on Thursday

CVS Health (NYSE:CVS) is expected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of $1.62 per share and revenue of $93.07 billion for the quarter. CVS Health has set its FY 2025 guidance at 5.750-6.000 EPS.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. On average, analysts expect CVS Health to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

CVS Health Trading Down 0.6 %

NYSE CVS opened at $64.91 on Tuesday. The stock has a market capitalization of $81.84 billion, a P/E ratio of 17.74, a P/E/G ratio of 0.98 and a beta of 0.57. CVS Health has a 52-week low of $43.56 and a 52-week high of $71.45. The firm has a 50-day moving average price of $66.45 and a 200 day moving average price of $58.75. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd will be issued a dividend of $0.665 per share. The ex-dividend date is Tuesday, April 22nd. This represents a $2.66 annualized dividend and a yield of 4.10%. CVS Health’s dividend payout ratio is currently 72.68%.

Insider Buying and Selling

In other CVS Health news, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the transaction, the senior vice president now owns 8,394 shares in the company, valued at $556,941.90. This trade represents a 47.23 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Michael F. Mahoney purchased 30,000 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was bought at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the acquisition, the director now owns 39,356 shares in the company, valued at $2,625,045.20. The trade was a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.22% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

CVS has been the subject of several analyst reports. UBS Group cut their price target on shares of CVS Health from $62.00 to $59.00 and set a “neutral” rating for the company in a report on Tuesday, February 11th. Morgan Stanley reaffirmed an “overweight” rating on shares of CVS Health in a report on Tuesday, April 15th. Argus set a $77.00 target price on shares of CVS Health in a report on Tuesday, February 18th. Piper Sandler increased their target price on shares of CVS Health from $72.00 to $74.00 and gave the company an “overweight” rating in a report on Friday, March 21st. Finally, Edward Jones raised shares of CVS Health from a “hold” rating to a “buy” rating in a report on Thursday, January 30th. Four investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $71.83.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.